On September 17, 2019 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that full data and additional exploratory analyses from the Phase 3 FORWARD I study evaluating mirvetuximab soravtansine compared to chemotherapy in women with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress to be held from September 27 to October 1, 2019 in Barcelona, Spain (Press release, ImmunoGen, SEP 17, 2019, View Source [SID1234539573]). Initial safety and overall response rate data from the Phase 1b FORWARD II triplet study evaluating mirvetuximab in combination with carboplatin and Avastin (bevacizumab) in patients with recurrent platinum-sensitive ovarian cancer will also be featured in a poster at the congress.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation Details
Title: "FORWARD I (GOG 3011): A Phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)" (Abstract #992O)
Date:September 29, 2019
Time:8:30 a.m. CEST/2:30 a.m. EDT
Lead Author:Kathleen Moore M.D., University of Oklahoma Health Sciences Center, Oklahoma City, OK
Poster Details
Title: "Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a Phase 1b study in patients with ovarian cancer" (Abstract #1028P)
Date:September 29, 2019
Time: 12:00 p.m. CEST/6:00 a.m. EDT
Lead Author: David M. O’Malley M.D., James Cancer Center and The Ohio State University Wexner Medical Center, Columbus, OH
Additional information and full abstracts can be found at www.esmo.org.
CONFERENCE CALL INFORMATION
ImmunoGen will hold a conference call at 8 a.m. ET on Monday, September 30, 2019. Dial-in details to follow.
ABOUT MIRVETUXIMAB SORAVTANSINE
Mirvetuximab soravtansine (IMGN853) is the first folate receptor alpha (FRα)-targeting ADC. It uses a humanized FRα-binding antibody to target the ADC specifically to FRα-expressing cancer cells and a potent anti-tumor agent, DM4, to kill the targeted cancer cells.